echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Novartis acquires Gyroscope, an ophthalmic gene therapy company, for $1.5 billion

    Novartis acquires Gyroscope, an ophthalmic gene therapy company, for $1.5 billion

    • Last Update: 2022-01-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 22, Novartis announced an agreement with Gyroscope Therapeutics, a British ophthalmic gene therapy company, to acquire the issued shares of the latter with a down payment of US$800 million, potential mileage of US$700 million, and a total transaction value of US$1.


    The core product GT005 of Gyroscope Therapeutics is a one-time gene therapy based on AAV2 vector, which is intended to be developed to treat age-related macular degeneration (AMD) secondary geographic atrophy


    GT005 can restore the balance of the over-activated complement system by promoting the secretion of complement factor I (CFI), relieve eye inflammation, and protect eyesight


    Age-related macular degeneration (AMD) is an eye disease that affects people's daily activities that require clear central vision (such as reading).


    Gyroscope Therapeutics is currently conducting a phase I/II and two phase II studies to evaluate the efficacy and safety of GT005 on AMD secondary geographic atrophy


    Novartis continues to increase its deployment in ophthalmology and gene therapy


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.